Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Esai Co., Ltd.

Kiyoshi Oketani

Manabu Murakami

Hideaki Fujisaki

Katsuya Tagami

Shuhei Miyazawa

Isao Yamatsu

Toshihiko Kaneko

Shigeru Souda

Seiichiro Nomoto

Norihiro Ueda

Naoyuki Shimomura

Hisashi Shibata

Makoto Okita

Masatoshi Fujimoto

Tsuneo Wakabayashi

Shinya Abe

Takeshi Suzuki

Shigeki Hibi

Yasushi Okamoto

Tetsuya Kawahara

Takashi Yamanaka

Masanobu Shinoda

Takashi Inoue

Naoki Kobayashi

Hirotoshi Numata

Akiharu Kajiwara

Kouji Nakamoto

Yuichi Inai

Nobuhisa Watanabe

Atsuhiko Kubota

Junichi Nagakawa

Hitoshi Harada

Masahiko Mori

Nobuyuki Yasuda

Toshiharu Ohgoh

Tomohisa Nakano

Kotaro Kodama

Hiroko Baba

It is an object of the present invention to provide a pharmaceutical composition comprising an anti-fractalkine antibody that provides therapeutically effective improvement to Crohn's disease, after the administration thereof to a human subject, and a method for treating Crohn's disease. Provided is a pharmaceutical composition for treating Crohn's disease. The present pharmaceutical composition comprises an anti-fractalkine antibody and a pharmaceutically acceptable excipient, and is used, such that the anti-fractalkine antibody is intravenously administered to a human at a dose of at least 10 mg/kg of human body weight in a method for treating Crohn's disease.

Method and pharmaceutical composition for treating Crohn's disease

A compound represented by the following general formula (1), or a salt or hydrate thereof: [Formula 1] wherein Rrepresents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, Rrepresents a hydrogen atom or a C1-C6 alkyl group, Rrepresents methyl or ethyl group, Rrepresents a C1-C6 alkyl group, Rrepresents a hydrogen atom, provided that a compound wherein Ris a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and Ris a hydrogen atom is excluded.

Imidazopyridine compound

Pyridine derivatives useful for preventing or treating peptic ulcers, pharmaceutical preparations and methods of treating peptic ulcers are described.

Pyridine derivatives having anti-ulcerative activity

Pyridine derivatives useful for preventing or treating peptic ulcers, pharmaceutical preparations and methods of treating peptic ulcers are disclosed.

A pyridine compound having the formula is disclosed and useful to treat the peptic ulcer. ##STR1## wherein R.sup.1 and R.sup.2 which may be the same or different are each a hydrogen atom, a lower alkyl group, a lower alkoxy group, a halogenated lower alkyl group, or a halogen atom, R.sup.3 and R.sup.4 which may be the same or different are each a hydrogen atom or a lower alkyl group, X is a group represented by the formula --S--, a group represented by the formula ##STR2## or a group represented by the formula ##STR3## and n is an integer of 1 to 6, provided that R.sup.3 and R.sup.4 are not simultaneously hydrogen atoms when n is 1.

Pyridine derivative and therapeutic agent for ulcer comprising the same

A benzothiazole derivative or a pharmacologically acceptable salt thereof of the following formula, as defined in the claims, which is useful as a preventive or therapeutic agent for diseases on which functions of suppressing leukotrienes and thromboxanes production are effective: ##STR1##

Benzothiazole compounds which are substituted by pyridymethyl

A benzothiazole derivative or a pharmacologically acceptable salt thereof which is useful as a preventive or therapeutic agent for diseases on which functions of suppressing leukotrienes and thromboxanes production are effective. A benzothiazole derivative represented by the following general formula (I): ##STR1##

Pyridyl substituted benzothiazole compounds which have useful

A benzothiazole derivative or a pharmacologically acceptable salt thereof which is useful as a preventive or therapeutic agent for diseases on which functions of suppressing leukotrienes and thromboxanes production are effective. A benzothiazole derivative represented by the following general formula (I): ##STR1## wherein R.sup.1 and R.sup.3 are either the same or different and represents a hydrogen atom, a lower alkyl group or a lower alkoxy group; R.sup.4 represents a group represented by the formula --(CH.sub.x)--.sub.q wherein q is a integer of from 1 to 4;

A pyridinium salt is useful as an antiulcer and is defined by the following formula. It includes a sulphenamide compound and a pyridinium compound. J is benzoimidazole, K is --S-- or --SSR, Z is hydroxy or oxyalkyl. ##STR1##

Pyridinium salt and pharmacological composition containing the same

A novel polyprenyl compound is identified with the formula and useful for a pharmaceutical drag. ##STR1## wherein X represents a group of the formula: ##STR2## (wherein R.sup.1 and R.sup.2, which may be the same or different, represent each a hydrogen atom, a lower alkyl group, a hydroxyalkyl group, or a lower alkenyl group); a group of the formula: ##STR3## (wherein A including the nitrogen atom shown represents a ring containing nitrogen and oxygen atoms); or a group of the formula: ##STR4## (wherein R.sup.3 represents a hydrogen atom or a lower alkyl group, and R.sup.4 represents a lower alkyl group); Y represents a group of the formula: ##STR5## or a group of the formula: ##STR6## (wherein R.sup.5 represents a hydrogen atom or a lower alkyl group), and n represents an integer of from 2 to 5.

Polyprenyl compound and pharmaceutical use

A novel polyprenyl compound is identified with the formula and useful for a pharmaceutical drag. ##STR1## wherein X represents a group of the formula: ##STR2## (wherein R.sup.1 and R.sup.2, which may be the same or differnt, represent each a hydrogen atom, a lower alkyl group, a hydroxyalkyl group, or a lower alkenyl group); a group of the formula: ##STR3## (wherein A including the nitrogen atom shown represents a ring containing nitrogen and oxygen atoms); or a group of the formula: ##STR4## (wherein R.sup.3 represents a hydrogen atom or a lower alkyl group, and R.sup.4 represents a lower alkyl group); Y represents a group of the formula: ##STR5## or a group of the formula: ##STR6## (wherein R.sup.5 represents a hydrogen atom or a lower alkyl group), and n represents an integer of from 2 to 5.

6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraene-2-ols of the general formula: ##STR1##

6,10,14,18-Tetramethly-5,9,13,17-nonadecatetraene-2-ol

Growing community of inventors

Ibaraki, Japan

Kiyoshi Oketani